The incidence of concomitant RV dysfunction at the time of CTRCD by RVFWLS has been recently studied in 30 patients with HER2+ breast cancer treated with trastuzumab with or without anthracyclines and concomitant RV dysfunction was seen in up to 40% of the patients18. The gene discussed is ERBB2; the disease is breast cancer.